TABLE 3.
Associations of survival outcomes with clinicopathologic characteristics in TCGA patients by univariate and multivariate analyses.
| Characteristics | Total (N) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Overall survival | |||||
| Clinical stage (Stage II & Stage III & Stage IV vs. Stage I) | 542 | 3.667 (2.377–5.657) | <0.001 | 3.071 (1.389–6.791) | 0.006 |
| Primary therapy outcome (CR vs. PD & SD & PR) | 474 | 0.131 (0.079–0.218) | <0.001 | 0.256 (0.111–0.586) | 0.001 |
| Radiation therapy (Yes vs. No) | 518 | 0.623 (0.402–0.964) | 0.034 | 0.348 (0.178–0.679) | 0.002 |
| GGH (High vs. Low) | 542 | 2.400 (1.553–3.709) | <0.001 | 2.442 (1.240–4.809) | 0.01 |
| Progression-free interval | |||||
| Clinical stage (Stage II & Stage III & Stage IV vs. Stage I) | 542 | 2.675 (1.870–3.827) | <0.001 | 2.224 (1.179–4.194) | 0.014 |
| Primary therapy outcome (CR vs. PD & SD & PR) | 474 | 0.120 (0.078–0.184) | <0.001 | 0.131 (0.066–0.262) | <0.001 |
| Disease-specific survival | |||||
| Clinical stage (Stage II & Stage III & Stage IV vs. Stage I) | 540 | 7.738 (4.102–14.596) | <0.001 | 5.030 (1.541–16.418) | 0.007 |
| Residual tumor (R1 & R2 vs. R0) | 409 | 5.839 (3.145–10.841) | <0.001 | 2.889 (1.106–7.551) | 0.03 |
| Primary therapy outcome (CR vs. PD & SD & PR) | 474 | 0.074 (0.042–0.131) | <0.001 | 0.161 (0.061–0.426) | <0.001 |
| GGH (High vs. Low) | 540 | 2.646 (1.533–4.566) | <0.001 | 3.167 (1.205–8.325) | 0.019 |